Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
6-Thioguanine, Capecitabine, Celecoxib + TMZ/CCNU in Recurrent Glioma
NCT00504660Phase 2Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Sep 2003
- Primary completion
- Aug 2010
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of tioguanine, capecitabine, celecoxib oral solution in anaplastic glioma, glioblastoma multiforme (GBM), sponsored by University of Texas MD Anderson Cancer Center. Started Sep 2003; status: completed.
02
Drugs
tioguaninecapecitabinecelecoxib oral solution
03
Conditions
anaplastic gliomaglioblastoma multiforme (GBM)
Beyond the preview
Go deeper on NCT00504660.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00504660.